Solid Tumor Panel Sequencing (500 genes)

Introduction

The Gene Panel is a new assay utilizing next generation sequencing (NGS) technology that allows for comprehensive genomic analysis of solid tumor samples. Because of the rigorously designed capture or amplicon sequencing strategy, Gene Panel makes NGS and data analysis more economical, flexible and efficient.

CD Genomics utilizes targeted genome sequencing to provide more efficient and accurate targeting of specific genes or mutations, and even detect low frequency variants in cancer-associated genes. Targeted genome sequencing facilitates the sequencing of a large number of genes and samples in a single, cost-effective assay.

We use capture-based next generation sequencing (Illumina platform) to target and analyze over 500 known tumor genes designed to detect variants and assess tumor mutational burden (TMB) and microsatellite instability (MSI) in tumor samples, allowing for the discovery of multiple positive tumor markers and novel drug targets at once. Our solid tumor panel sequencing service can be used to detect formalin-fixed, paraffin-embedded (FFPE) tissues such as lung cancer, melanoma cancer, ovarian cancer, and gastric cancer, etc. We also provide custom bioinformatics analysis services for you to perform targeted tumor gene analysis and comparative tumor tissue analysis in a short time, etc.

Highlights of Our Solid Tumor Panel Sequencing Service

Extensive coverage of many solid tumor mutation genes, with one-time detection of over 500 genes
Detect low-frequency mutations with high analytical sensitivity >96%
High specificity and homogeneity sequencing data (>98%) using high-efficiency capture enrichment technology
Uniform coverage of GC-rich and complex regions for high-quality sequencing data
Complete NGS workflow for customized services from sequencing to bioinformatics analysis
Identify different variant classes for known cancer related genes, such as CNV, indel, SNV, gene fusion, transcript variation

We Can Help You With

Analysis of molecular mechanisms in tumor formation – identification of important driver mutations in solid tumor samples
Tumor development and evolution studies
Tumor heterogeneity research - including analysis of inter-individual, inter-cellular and intra-tumor heterogeneity
Detection of immuno-oncology biomarkers, including genomic instability and TMB
Research and development of new drugs and therapies

Gene List of Solid Tumor Panel (500 genes)

ABL1	ABL2	ACVR1	ACVR1B	AKT1	AKT2	AKT3	ALK	ALOX12B	ANKRD11
ANKRD26	APC	AR	ARAF	ARFRP1	ARID1A	ARID1B	ARID2	ARID5B	ASXL1
ASXL2	ATM	ATR	ATRX	AURKA	AURKB	AXIN1	AXIN2	AXL	B2M
BAP1	BARD1	BBC3	BCL10	BCL2	BCL2L1	BCL2L11	BCL2L2	BCL6	BCOR
BCORL1	BCR	BIRC3	BLM	BMPR1A	BRAF	BRCA1	BRCA2	BRD4	BRIP1
BTG1	BTK	C11orf30	CALR	CARD11	CASP8	CBFB	CBL	CCND1	CCND2

(Check the Gene List of Solid Tumor Panel (500 genes) for more genes.)

Service Specifications

Sample Requirements

Sample types: genomic DNA, formalin-fixed paraffin-embedded (FFPE) tissues
Recommended amount: 2 μg
Minimum amount: 40 ng DNA, 40 ng RNA

Collection: DNA samples (stored in TE buffer or equivalent), FFPE samples (recommended cryopreservation). Please make sure that the DNA is not degraded.

Sequencing

Illumina PE150
Enrichment Method: Hybrid-capture enrichment
More than 80% of bases with a ≥ Q30 quality score
Recommended sequencing depth: ≥ 1000x

Bioinformatics Analysis

Turnaround time: within 6 weeks
Primary analysis: read alignment, SNP/Indel/CNV annotation
Secondary analysis: statistical and pathway analysis, NMF mutation characterization, driver gene prediction
Tertiary analysis: susceptibility gene screening, variants analysis, structure analysis
Custom bioinformatics analysis

Solid Tumor Panel Workflow

CD Genomics concentrates on disease genomics and our rapid NGS workflow, which maximize efficient and cost effective solid tumor panel sequencing services and bioinformatics support for our clients.

Gene Panel Workflow

* For Research Use Only. Not for use in diagnostic procedures.